Madrigal Pharmaceuticals Inc. (MDGL) Has Surged To A New High On Study Results

Madrigal Pharmaceuticals Inc. (MDGL) announced Wednesday morning that its Phase 2 trial of MGL-3196, in patients with biopsy-proven non-alcoholic steatohepatitis, met its primary endpoint.

from RTT - Hot Stocks http://ift.tt/2AxIqgH
via IFTTT